TAFI

TAFI (Thrombin-Activatable Fibrinolysis Inhibitor, Carboxypeptidase B2) deficient plasma from 5-Diagnostics for research into fibrinolysis regulation and the thrombin-thrombomodulin-TAFI axis.

TAFI is a plasma zymogen activated by the thrombin-thrombomodulin complex on the endothelial surface — active TAFIa removes C-terminal lysine residues from partially degraded fibrin, eliminating plasminogen binding sites and dramatically attenuating fibrinolysis. TAFI thus links the coagulation and fibrinolytic systems as a feedback mechanism that protects against premature clot dissolution.

5-Diagnostics TAFI-deficient plasma is produced by immunodepletion of TAFI/CPB2 from human citrated plasma, with residual TAFI confirmed below 1% by ELISA and/or chromogenic carboxypeptidase activity assay.

TAFI-deficient plasma is used to study the role of TAFI in clot lysis time assays (plasma clot lysis assay, thromboelastographic endpoints), to validate TAFI activity assays by reconstruction experiments, and in basic research characterizing the TAFI pathway in thrombosis and stroke models.

Compatible with plasma clot lysis assay formats and thrombin generation assay systems incorporating fibrinolysis. Lot-specific certificates include TAFI antigen (ng/mL) and residual CPB2 activity. For Research Use Only. Not for use in diagnostic procedures.